{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:58:09Z","timestamp":1793383089263,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging"],"abstract":"<jats:p>Natural autoantibodies (NAbs) are a key component of the immune system, produced mainly by B-1 cells without prior antigenic stimulation. These antibodies exhibit broad reactivity toward both self and non-self antigens and contribute to immune homeostasis by clearing apoptotic cells and cellular debris, modulating immune responses, preventing autoimmune reactions, and promoting tissue repair. NAbs are present in intravenous immunoglobulin (IVIg) preparations, where they play an important role in the therapeutic effects observed in autoimmune, inflammatory, and neurodegenerative diseases. Importantly, NAbs of the IgG class contained in commercial IVIg originate from large-scale pooling of sera from thousands of healthy donors, and are recovered after multiple enrichment and purification steps during the manufacturing process. This review provides a comprehensive overview of the physiological functions of NAbs and their involvement in the mechanisms of action of IVIg. The review particularly focuses on anti-idiotypic antibodies within IVIg, which can neutralize pathogenic autoantibodies in diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and pemphigus vulgaris. In the neurological field, NAbs in IVIg have been shown to target misfolded proteins such as amyloid-beta and alpha-synuclein, reduce neuroinflammation, and support neuronal survival, with promising results in Alzheimer\u2019s disease, Parkinson\u2019s disease, autoimmune encephalitis, and small fiber neuropathy. Similarly, in dermatological and systemic autoimmune diseases, NAbs contribute to immune regulation and the neutralization of tissue-damaging autoantibodies. Enhancing the therapeutic potential of IVIg through selective enrichment of beneficial NAb subsets could represent a promising direction for future research aimed at improving outcomes in a wide range of immune-mediated diseases.<\/jats:p>","DOI":"10.3389\/fragi.2025.1682457","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:27:52Z","timestamp":1759318072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Natural autoantibodies and their functional therapeutic roles in intravenous immunoglobulin"],"prefix":"10.3389","volume":"6","author":[{"given":"Maria Giovanna","family":"Danieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Claudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gammeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda Julyus","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2317762121","DOI":"10.1073\/pnas.2317762121","article-title":"Restoring immune tolerance in pemphigus vulgaris","volume":"121","author":"Ahmed","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13075-021-02581-0","article-title":"Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events","volume":"23","author":"Ajeganova","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0202954","DOI":"10.1371\/journal.pone.0202954","article-title":"Extending the functional characteristics of naturally occurring autoantibodies against \u03b2-Amyloid, Prion Protein and \u03b1-Synuclein","volume":"13","author":"Albus","year":"2018","journal-title":"PLOS ONE"},{"key":"B5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0167-5699(05)80045-3","article-title":"Natural autoantibodies: from \u2018horror autotoxicus\u2019 to \u2018gnothi seauton","volume":"12","author":"Avrameas","year":"1991","journal-title":"Immunol. Today"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2013.01.006","article-title":"Natural autoantibodies in the physiology and pathophysiology of the immune system","volume":"41","author":"Avrameas","year":"2013","journal-title":"J. Autoimmun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3389\/fimmu.2018.01320","article-title":"Natural autoantibodies: an Undersugn hero of the immune system and autoimmune disorders\u2014a point of view","volume":"9","author":"Avrameas","year":"2018","journal-title":"Front. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4614-3461-0_7","article-title":"Naturally occurring autoantibodies against \u03b2-amyloid","volume":"750","author":"Bach","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JAD-2010-1353","article-title":"Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta","volume":"20","author":"Balakrishnan","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1385\/CRIAI:29:3:213","article-title":"Toward molecular targeting with specific intravenous immunoglobulin preparation","volume":"29","author":"Blank","year":"2005","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/intimm\/dxm052","article-title":"The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model","volume":"19","author":"Blank","year":"2007","journal-title":"Int. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-62703-586-6_18","article-title":"Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases","volume":"1060","author":"Blank","year":"2014","journal-title":"Methods Mol. Biol. Clifton NJ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10875-014-0019-2","article-title":"Natural autoantibodies to Fc\u03b3 receptors in intravenous immunoglobulins","volume":"34","author":"Bouhlal","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/biom12030469","article-title":"Alpha-synuclein-specific naturally occurring antibodies inhibit aggregation in vitro and in vivo","volume":"12","author":"Braczynski","year":"2022","journal-title":"Biomolecules"},{"key":"B15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1586\/1744666X.2015.1044980","article-title":"The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease","volume":"11","author":"Burns","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2174\/1567205017666200102151731","article-title":"Effect of different A\u03b2 aggregates as antigen on the measure of naturally occurring autoantibodies against amyloid-\u03b240\/42 in IVIG","volume":"16","author":"Cao","year":"2020","journal-title":"Curr. Alzheimer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaci.2014.06.029","article-title":"Auto-anti-IgE: naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation","volume":"134","author":"Chan","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1086\/513801","article-title":"Anti-tubulin autoantibodies in acquired demyelinating polyneuropathies","volume":"176","author":"Connolly","year":"1997","journal-title":"J. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"ProCID Investig. Brain."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1589191","DOI":"10.1155\/2020\/1589191","article-title":"Epigenetic therapy as a putative molecular target to modulate B cell biology and behavior in the context of immunological disorders","volume":"2020","author":"da Costa","year":"2020","journal-title":"J. Immunol. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1254854","DOI":"10.3389\/fnmol.2023.1254854","article-title":"A role for pathogenic autoantibodies in small fiber neuropathy?","volume":"16","author":"Daifallah","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"103710","DOI":"10.1016\/j.autrev.2024.103710","article-title":"Intravenous immunoglobulin as a therapy for autoimmune conditions","volume":"24","author":"Danieli","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13311-019-00796-3","article-title":"Anti-neuronal antibodies within the IVIg preparations: importance in clinical practice","volume":"17","author":"Dimitriadou","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4939-8958-4_3","article-title":"IgM natural autoantibodies in physiology and the treatment of disease","volume-title":"Human monoclonal antibodies","author":"Fereidan-Esfahani","year":"2019"},{"key":"B25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaci.2018.10.064","article-title":"Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE","volume":"144","author":"Galeotti","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41423-019-0334-x","article-title":"Anti-IgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation","volume":"17","author":"Galeotti","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5623","DOI":"10.4049\/jimmunol.0802412","article-title":"IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation","volume":"182","author":"Garaud","year":"2009","journal-title":"J. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109039","DOI":"10.1016\/j.clim.2022.109039","article-title":"Intravenouse immunoglobuline in dysautonomia","volume":"240","author":"Gavrilova","year":"2022","journal-title":"Clin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1212\/WNL.0000000000011921","article-title":"IVIG and small fiber neuropathy: the ongoing search for evidence","volume":"96","author":"Gibbons","year":"2021","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.atherosclerosis.2014.07.030","article-title":"Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men","volume":"236","author":"Gigante","year":"2014","journal-title":"Atherosclerosis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10875-014-0025-4","article-title":"Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease","author":"Gr\u00f6nwall","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/ar2507","article-title":"Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis","volume":"10","author":"Gy\u00f6rgy","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10072-011-0506-7","article-title":"Downbeat nystagmus, ataxia and spastic tetraparesis due to coeliac disease","volume":"32","author":"Habek","year":"2011","journal-title":"Neurol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e072134","DOI":"10.1136\/bmjopen-2023-072134","article-title":"Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial","volume":"13","author":"Hill","year":"2023","journal-title":"BMJ Open"},{"key":"B77","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.nbd.2018.11.024","article-title":"Naturally occurring autoantibodies against \u03b1-synuclein rescues memory and motor deficits and attenuates \u03b1-synuclein pathology in mouse model of Parkinson\u2019s disease. Neurobiol","volume":"124","author":"Huang","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.nbd.2018.11.024","article-title":"Naturally occurring autoantibodies against \u03b1-synuclein rescues memory and motor deficits and attenuates \u03b1-synuclein pathology in mouse model of Parkinson\u2019s disease","volume":"124","author":"Huang","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/CON.0000000000001448","article-title":"Autoimmune encephalitis","volume":"30","author":"Irani","year":"2024","journal-title":"Contin. (Minneap Minn)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065x.1984.tb00484.x","article-title":"Idiotypic networks and other preconceived ideas","volume":"79","author":"Jerne","year":"1984","journal-title":"Immunol. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e70491","DOI":"10.1002\/brb3.70491","article-title":"Does the use of intravenous immunoglobulin improve clinical outcomes in adults with autoimmune encephalitis? A systematic review","volume":"15","author":"Kaira","year":"2025","journal-title":"Brain Behav."},{"key":"B39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clim.2019.07.007","article-title":"West Nile Virus infection triggering autoimmune encephalitis: pathophysiological and therapeutic implications","volume":"207","author":"Karagianni","year":"2019","journal-title":"Clin. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-7180-0","volume-title":"Natural antibodies","author":"Kaveri","year":"2017"},{"key":"B42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2006.11.002","article-title":"Idiotypic and anti-idiotypic elastin autoantibodies: implications for IVIg and pregnancy loss","volume":"28","author":"Konova","year":"2007","journal-title":"J. Autoimmun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jneuroim.2017.12.003","article-title":"Serum titers of autoantibodies against \u03b1-synuclein and tau in child- and adulthood","volume":"315","author":"Kuhn","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0195346","DOI":"10.1371\/journal.pone.0195346","article-title":"Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells","volume":"13","author":"Kuret","year":"2018","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/acn3.51540","article-title":"The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis","volume":"9","author":"Lee","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/82_2017_37","article-title":"Role of natural IgM autoantibodies (IgM-NAA) and IgM anti-leukocyte antibodies (IgM-ALA) in regulating inflammation","volume":"408","author":"Lobo","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-a\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"B48","first-page":"1","article-title":"Intravenous IgG: biological modulating molecules","volume":"23","author":"Luzi","year":"2009","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1742-2094-7-90","article-title":"Human intravenous immunoglobulin provides protection against A\u03b2 toxicity by multiple mechanisms in a mouse model of Alzheimer\u2019s disease","volume":"7","author":"Magga","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41467-021-22458-9","article-title":"B1a and B2 cells are characterized by distinct CpG modification states at DNMT3A-maintained enhancers","volume":"12","author":"Mahajan","year":"2021","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"653734","DOI":"10.3389\/fneur.2021.653734","article-title":"Treatment approaches for atypical CIDP","volume":"12","author":"Menon","year":"2021","journal-title":"Front. Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.autrev.2013.01.003","article-title":"The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease","volume":"12","author":"Miescher","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2249.2010.04265.x","article-title":"Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris","volume":"162","author":"Mimouni","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","article-title":"Control of early viral and bacterial distribution and disease by natural antibodies","volume":"286","author":"Ochsenbein","year":"1999","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.neulet.2019.04.004","article-title":"Effect of naturally occurring \u03b1-synuclein-antibodies on toxic \u03b1-synuclein-fragments","volume":"704","author":"Rabenstein","year":"2019","journal-title":"Neurosci. Lett."},{"key":"B56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.medcli.2011.11.022","article-title":"Inmunoglobulinas intravenosas: llave inmunomoduladora del sistema inmunol\u00f3gico","volume":"139","author":"Ramos-Medina","year":"2012","journal-title":"Med. Cl\u00ednica"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1212\/01.wnl.0000345662.05861.e4","article-title":"Invited article: human natural autoantibodies in the treatment of neurologic disease","volume":"72","author":"Rodriguez","year":"2009","journal-title":"Neurology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1038\/cti.2015.18","article-title":"Immunological evidence and regulatory potential for cell\u2010penetrating antibodies in intravenous immunoglobulin","volume":"4","author":"Sali","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10875-024-01805-7","article-title":"Levels of natural antibodies before and after immunoglobulin replacement treatment affect the clinical phenotype in Common variable immunodeficiency","volume":"45","author":"Sarrigeorgiou","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1398-9995.2011.02579.x","article-title":"Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes: Siglec-9 autoantibodies and anti-idiotypes in dimeric IVIG","volume":"66","author":"Schaub","year":"2011","journal-title":"Allergy"},{"key":"B62","first-page":"193","article-title":"Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation","volume":"49","author":"Schluter","year":"2003","journal-title":"Cell Mol. Biol. Noisy--Gd Fr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2249.2009.04026.x","article-title":"Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation","volume":"158","author":"Schwartz-Albiez","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","article-title":"What is the contents of the magic draft IVIg?","volume":"7","author":"Seite","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxf099","article-title":"Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus","volume":"14","author":"Shoenfeld","year":"2002","journal-title":"Int. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.3390\/ijms21155295","article-title":"The functional roles and applications of immunoglobulins in neurodegenerative disease","volume":"21","author":"Sim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/rheumatology\/ken120","article-title":"Natural antibodies against phosphorylcholine as potential protective factors in SLE","volume":"47","author":"Su","year":"2008","journal-title":"Rheumatology."},{"key":"B68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.autrev.2008.03.007","article-title":"Natural human antibodies to amyloid beta peptide","volume":"7","author":"Szabo","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"B69","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.clim.2011.12.014","article-title":"IVIg-mediated inhibition of antigen presentation: predominant role of naturally occurring cationic IgG","volume":"142","author":"Tr\u00e9panier","year":"2012","journal-title":"Clin. Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIg perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"B71","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.autrev.2008.03.015","article-title":"Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg)","volume":"7","author":"Von Gunten","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.neuropharm.2016.02.015","article-title":"Naturally occurring autoantibodies against A\u03b2 oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer\u2019s disease than intravenous immunoglobulin","volume":"105","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/0891693031000080228","article-title":"Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations--possible immunomodulation of atherosclerosis","volume":"36","author":"Wu","year":"2003","journal-title":"Autoimmunity"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41423-022-00933-7","article-title":"Epigenetic regulation of B cells and its role in autoimmune pathogenesis","volume":"19","author":"Xiao","year":"2022","journal-title":"Cell Mol. Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"790962","DOI":"10.3389\/fimmu.2021.790962","article-title":"Immunotherapy for refractory autoimmune encephalitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1177\/0961203309106921","article-title":"Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside","volume":"18","author":"Zandman-Goddard","year":"2009","journal-title":"Lupus"}],"container-title":["Frontiers in Aging"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2025.1682457\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:27:54Z","timestamp":1759318074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fragi.2025.1682457\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":77,"alternative-id":["10.3389\/fragi.2025.1682457"],"URL":"https:\/\/doi.org\/10.3389\/fragi.2025.1682457","relation":{},"ISSN":["2673-6217"],"issn-type":[{"value":"2673-6217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1682457"}}